SCHEMBL30765803

SCHEMBL30765803

O=C(O)Cn1c(-c2ccccc2)ncc(NC(=O)c2ccc(Oc3ccccc3)s2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 5/20 0.47
ELANE P08246 12/20 0.42
ITK Q08881 1/20 0.37
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765787 0.92 CASP1 (0.44) CASP1ELANEITK
SCHEMBL30765632 0.80 CASP1 (0.42) CASP1ELANE
SCHEMBL6240894 0.79 ELANE (0.51) CASP1ELANEMAPT
SCHEMBL5728202 0.78 ELANE (0.54) CASP1ELANE
SCHEMBL6240974 0.74 RAB9A (0.55) CASP1ELANEMAPT
SCHEMBL6799310 0.74 RAB9A (0.54) CASP1ELANE
SCHEMBL30765807 0.74 CASP1 (0.47) CASP1ELANE
SCHEMBL31558574 0.73 ELANE (0.46) CASP1ELANE
SCHEMBL6805801 0.73 RAB9A (0.53) CASP1ELANEMAPT
SCHEMBL30766127 0.73 TUBB4A (0.51) CASP1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed